Live Chat

FDA Identifies Risks for Transvaginal Mesh Surgeries

Food and Drug Administration (FDA) research into health outcomes has determined that transvaginal mesh operations have greater risks than traditional pelvic organ prolapse (POP) and stress urinary incontinence (SUI) surgeries. Additionally, transvaginal mesh operations tend not to improve patient health quality more than traditional approaches and in many cases have failed to address POP and SUI symptoms at all.

 

The FDA’s research findings surprise many transvaginal mesh patients. For a large and growing number of patients, conversations with their health care provider and their own research left them with the impression that transvaginal mesh procedures were much safer than FDA findings suggest.

 

Are you ready to find out if your legal rights were violated as a result of incomplete or ineffective communication about the risks of your transvaginal mesh procedure? If you’re still suffering from the effects of POP or SUI even after a mesh surgery, the time may be right to speak with a professional at the law firm of Fears Nachawati. For your free consultation, call us at 1.866.545.8364 or email mn@fnlawfirm.com. Let us help you.

Categories
Drug Litigation

FDA Identifies Risks for Transvaginal Mesh Surgeries